ArticleNPJ biofilms and microbiomes2025
Characterizing interactions of Staphylococcus aureus and Escherichia coli in dual-species implant-associated biofilms.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Arginine-substituted Mastoparan-C derivatives combat dual bacterial pathogens:Microbiology spectrum · 2026Article
- Ultrasound-activated piezoelectric Bi@Bi-MOF enables STING-mediated immunotherapy for implant-associated infections.Journal of nanobiotechnology · 2026Article
- Treatment Options in Managing Infections Following Calcaneal Fractures: A Systematic Review.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
While Staphylococcus aureus is the predominant pathogen in periprosthetic joint infections (PJI), polymicrobial infections involving Gram-negative organisms, such as Escherichia coli, complicate clinical outcomes. Little is known regarding implant-associated polymicrobial interactions; consequently, current PJI treatments are not optimized for their treatment. This study explored the dynamics of S. aureus-E. coli dual-species biofilms, focusing on biofilm properties, antibiotic susceptibility, and molecular interactions. Co-culture experiments revealed that E. coli significantly suppressed S. aureus biofilm viability, observed for methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). Microscopic analyses demonstrated enhanced E. coli attachment facilitated by S. aureus matrix proteins; however, over time, E. coli dominated the biofilm composition. In the presence of E. coli, MSSA biofilm exhibited improved gentamicin susceptibility while MRSA showed limited change, underscoring strain-specific interactions. Notably, E. coli biofilms exhibited enhanced resistance to gentamicin in dual-species settings. Gene expression profiling revealed molecular adaptation in S. aureus and E. coli, triggered by the differential regulation of stress, adhesion, virulence, and biofilm-associated genes within a dual-species implant-associated biofilm. The suppression of S. aureus by E. coli presents potential therapeutic avenues, and in vivo studies and mechanistic investigations are crucial for optimizing treatment strategies targeting polymicrobial PJIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.